Jean Saunders, MD
Family Medicine · Prairieville, LANPI 1396735270
Payments from drug & device makers
Across 328 payments — averaging $12.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amarin Pharma, Inc.$407
- Novo Nordisk$350
- Pfizer$317
- Takeda Pharmaceuticals U.S.A., Inc.$300
- GSK$240
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $1,128 |
| Amarin Pharma, Inc. | 29 | $407 |
| Novo Nordisk | 22 | $350 |
| Pfizer | 25 | $317 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $300 |
| GSK | 21 | $240 |
| Jazz Pharmaceuticals Inc. | 7 | $148 |
| Abbott | 6 | $119 |
| Sanofi-aventis U.S. LLC | 8 | $109 |
| Amgen | 6 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Lilly USA, LLC | 5 | $86 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Johnson & Johnson | 5 | $75 |
| Bayer | 4 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $59 |
| Boehringer Ingelheim | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Eisai Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $34 |
| Exact Sciences | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $28 |
| Merck | 2 | $25 |
| Tris Pharma Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Novartis | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$115
How this compares
$4,093 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 245 | $315,007 |
| OzempicSemaglutide | 167 | $211,836 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $100,230 |
| JardianceEmpagliflozin | 82 | $82,371 |
| EliquisApixaban | 72 | $73,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $49,547 |
| LinzessLinaclotide | 70 | $43,274 |
| MyrbetriqMirabegron | 49 | $29,925 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $20,352 |
| KerendiaFinerenone | 23 | $14,582 |
| XareltoRivaroxaban | 22 | $12,911 |
| TrulicityDulaglutide | 13 | $12,655 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,078 |
| Repatha SureclickEvolocumab | 13 | $10,747 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $9,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $86 | $327,662258 claims |
| Novo NordiskOzempic | $350 | $211,836167 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $51 | $92,20095 claims |
| PfizerEliquis | $317 | $73,86672 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $240 | $60,626102 claims |
| AbbVieLinzess | $1,128 | $43,27470 claims |
| MerckJanumet | $25 | $20,35217 claims |
| BayerKerendia | $61 | $14,58223 claims |
| Johnson & JohnsonXarelto | $75 | $12,91122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Prairieville
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.